Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Tamsulosin

From Pharmacopedia
Revision as of 10:43, 23 May 2026 by MDElliottMD (talk | contribs) (home-claude category backfill (parser-claude gap closure))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Starting dose
0.4 mg PO once daily, 30 minutes after the same meal each day
Preparations
0.4 mg capsules
US FDA Max
0.8 mg/d (rarely needed)
Pharmacology
Routes
Oral
Onset
Symptom improvement within 1 week; peak effect at 4-6 weeks
Duration
24 hours
Half-life
9-15 hours[1]
Bioavailability
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)[1]
Pregnancy
Not applicable (male indication); historical Category B if used in unrelated female cases.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Tamsulosin selectively antagonizes α1A adrenergic receptors, the dominant subtype in prostatic and bladder-neck smooth muscle, relaxing outflow tract tone and improving urodynamic flow with less peripheral hypotension than non-selective α-blockers.0 CYP3A4 and CYP2D6 substrate. The α1A-selective binding underlies intraoperative floppy iris syndrome (IFIS), a recognized cataract-surgery complication that does not reverse after stopping the drug; preoperative disclosure is standard[1].

References

  1. 1.0 1.1 1.2 FDA Prescribing Information, Flomax (tamsulosin HCl), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020579s044lbl.pdf